Sihuan Pharmaceutical Holdings Group Ltd. provided preliminary unaudited consolidated earnings guidance for the year ended 31 December 2019. For the year, the Group is expected to record a net loss of not less than RMB 2.5 billion for the year, mainly attributable to the recognition of various impairment losses for the Year, including but not limited to, the impairment losses on goodwill recognized for the first half of 2019.